-transparent.png){kind=logo}
Attenuated Salmonella typhi vaccine strain CVD 908, which harbors deletion mutations in aroC and aroD, has been shown to be well-tolerated and highly immunogenic, eliciting impressive serum antibody, mucosal IgA and cell-mediated immune responses. A further derivative prepared by introducing a deletion in htrA (which encodes a heat-shock protein that also has activity as a serine protease in CVD 908 (Chatfield et al., unpublished data) resulted in CVD 908-htrA. In phase 1 clinical trials, CVD 908-htrA appears very attractive as a live oral vaccine candidate. Both CVD 908 and CVD 908-htrA are useful as live vector vaccines to deliver foreign antigens to the immune system. Conditions that enhance the expression and immunogenicity of foreign antigens carried by CVD 908 and CVD 908-htrA are being investigated.
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
January 2017,
Frontiers in immunology,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
January 1995,
Parasitology,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
August 1991,
Journal of immunological methods,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
January 1990,
Research in microbiology,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
January 2017,
The Journal of infectious diseases,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
January 2003,
Vaccine,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
May 2006,
Vaccine,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
November 2012,
Vaccine,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
October 2009,
Current opinion in molecular therapeutics,
M M Levine, and
J Galen, and
E Barry, and
F Noriega, and
S Chatfield, and
M Sztein, and
G Dougan, and
C Tacket
February 2003,
Current opinion in molecular therapeutics,
